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BACKGROUND: Glioblastomas (GB) are the most common and lethal primary brain
tumors. Significant progress has been made toward identifying potential risk factors
for GB and diagnostic and prognostic biomarkers. However, the current standard of
care for newly diagnosed GB, the Stupp protocol, has remained unchanged for over a
decade. Large-scale translational programs based on a large clinicobiological
database are required to improve our understanding of GB biology, potentially
facilitating the development of personalized and specifically targeted therapies. With
this goal in mind, a well-annotated clinicobiological database housing data and
samples from GB patients has been set up in France: the French GB biobank (FGB).
METHODS: The biobank contains data and samples from adult GB patients from 24
centers in France providing written informed consent. Clinical and biomaterial data
are stored in anonymized certified electronic case report forms. Biological samples
(including frozen and formalin-fixed paraffin-embedded tumor tissues, blood samples,
and hair) are conserved in certified biological resource centers or tumor tissue banks
at each participating center.
RESULTS: Clinical data and biological materials have been collected for 1087 GB
patients. A complete set of samples (tumor, blood and hair) is available for 66%, and
at least one frozen tumor sample is available for 88% of the GB patients.
CONCLUSIONS: This large biobank is unique in Europe and can support the large-
scale translational projects required to improve GB care. Additional biological
materials, such as peritumoral brain zone and fecal samples, will be collected in the
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